Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03265080 · ClinicalTrials.gov registry record · Phase 1
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
A Phase 1 study, sponsored by Advaxis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03265080: Clinical Trial Phase 1 study, sponsored by Advaxis.
NCT03265080 is a Phase 1 study that was terminated before completion, run by Advaxis. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03265080, a Phase 1 study, was terminated before completion, sponsored by Advaxis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL ADXS-NEO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03265080
The ClinicalTrials.gov registry entry for NCT03265080 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advaxis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03265080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03265080 about?
NCT03265080 is a clinical study titled "A Study of ADXS-NEO Expressing Personalized Tumor Antigens". This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).
What is the current status of trial NCT03265080?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-03-28. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT03265080?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), ADXS-NEO (BIOLOGICAL).
Who is sponsoring clinical trial NCT03265080?
This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.